BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 14986690)

  • 1. Tadalafil: new preparation. Slightly more convenient, but poorly assessed in organic disorders.
    Prescrire Int; 2003 Dec; 12(68):213-5. PubMed ID: 14986690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST
    Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil and erectile dysfunction: new preparation. Helpful.
    Prescrire Int; 1998 Dec; 7(38):163-5. PubMed ID: 10848044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners.
    Brock G; Chan J; Carrier S; Chan M; Salgado L; Klein AH; Lang C; Horner R; Gutkin S; Dickson R
    BJU Int; 2007 Feb; 99(2):376-82. PubMed ID: 17155989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers.
    Carson C; Shabsigh R; Segal S; Murphy A; Fredlund P; Kuepfer C;
    Urology; 2005 Feb; 65(2):353-9. PubMed ID: 15708052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.
    Lee J; Pommerville P; Brock G; Gagnon R; Mehta P; Krisdaphongs M; Chan M; Chan J; Dickson R
    BJU Int; 2006 Sep; 98(3):623-9. PubMed ID: 16925764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
    Kloner RA; Jackson G; Hutter AM; Mittleman MA; Chan M; Warner MR; Costigan TM; Vail GM
    Am J Cardiol; 2006 Jun; 97(12):1778-84. PubMed ID: 16765134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S
    Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
    Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
    Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
    Eardley I; Gentile V; Austoni E; Hackett G; Lembo D; Wang C; Beardsworth A
    BJU Int; 2004 Oct; 94(6):871-7. PubMed ID: 15476525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic dilemma: how to use tadalafil.
    Carosa E; Lombardo F; Martini P; Brandetti F; Jannini EA
    Int J Androl; 2005 Dec; 28 Suppl 2():74-80. PubMed ID: 16236070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.
    Ahn TY; Lee SW; Kim SW; Yang DY; Park NC; Min KS; Park K; Paick JS; Dyachkova Y; Dwight T; Lee MS
    Asian J Androl; 2007 Nov; 9(6):760-70. PubMed ID: 17968461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction.
    Skoumal R; Chen J; Kula K; Breza J; Calomfirescu N; Basson BR; Kopernicky V
    Eur Urol; 2004 Sep; 46(3):362-9; discussion 369. PubMed ID: 15306109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New treatment options for erectile dysfunction. Pharmacologic and nonpharmacologic options].
    Sperling H; Lümmen G; Schneider T; Rübben H
    Herz; 2003 Jun; 28(4):314-24. PubMed ID: 12825147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.
    Dresser MJ; Desai D; Gidwani S; Seftel AD; Modi NB
    Int J Impot Res; 2006; 18(1):104-10. PubMed ID: 16307008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.
    Young JM; Feldman RA; Auerbach SM; Kaufman JM; Garcia CS; Shen W; Murphy AM; Beasley CM; Hague JA; Ahuja S
    J Androl; 2005; 26(3):310-8. PubMed ID: 15866997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging oral drugs for erectile dysfunction.
    Briganti A; Salonia A; Gallina A; Suardi N; Rigatti P; Montorsi F
    Expert Opin Emerg Drugs; 2004 May; 9(1):179-89. PubMed ID: 15155143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.